Utilize este identificador para referenciar este registo: https://hdl.handle.net/10216/127389
Autor(es): Gaspar, L
Coron, R
KongThoo Lin, P
Costa, DM
Perez-Cabezas, B
Tavares, J
Roura-Ferrer, M
Ramos, I
Ronin, C
Major, L
Ciesielski, F
Pemberton, I
MacDougall, J
Ciapetti, P
Smith, TK
Cordeiro-da-Silva, A
Título: Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease
Editor: Public Library of Science
Data de publicação: 2018
Resumo: Chagas disease remains one of the most neglected diseases in the world despite being the most important parasitic disease in Latin America. The characteristic chronic manifestation of chagasic cardiomyopathy is the region’s leading cause of heart-related illness, causing significant mortality and morbidity. Due to the limited available therapeutic options, new drugs are urgently needed to control the disease. Sirtuins, also called Silent information regulator 2 (Sir2) proteins have long been suggested as interesting targets to treat different diseases, including parasitic infections. Recent studies on Trypanosoma cruzi sirtuins have hinted at the possibility to exploit these enzymes as a possible drug targets. In the present work, the T. cruzi Sir2 related protein 1 (TcSir2rp1) is genetically validated as a drug target and biochemically characterized for its NAD+-dependent deacetylase activity and its inhibition by the classic sirtuin inhibitor nicotinamide, as well as by bisnaphthalimidopropyl (BNIP) derivatives, a class of parasite sirtuin inhibitors. BNIPs ability to inhibit TcSir2rp1, and anti-parasitic activity against T. cruzi amastigotes in vitro were investigated. The compound BNIP Spermidine (BNIPSpd) (9), was found to be the most potent inhibitor of TcSir2rp1. Moreover, this compound showed altered trypanocidal activity against TcSir2rp1 overexpressing epimastigotes and anti-parasitic activity similar to the reference drug benznidazole against the medically important amastigotes, while having the highest selectivity index amongst the compounds tested. Unfortunately, BNIPSpd failed to treat a mouse model of Chagas disease, possibly due to its pharmacokinetic profile. Medicinal chemistry modifications of the compound, as well as alternative formulations may improve activity and pharmacokinetics in the future. Additionally, an initial TcSIR2rp1 model in complex with p53 peptide substrate was obtained from low resolution X-ray data (3.5 Å) to gain insight into the potential specificity of theinter-action with the BNIP compounds. In conclusion,thesearch for TcSir2rp1 specific inhibitors may representa valuable strategy for drug discovery against T.cruzi.
URI: https://hdl.handle.net/10216/127389
Fonte: PLoS Neglected Tropical Diseases, vol.12(1):e0006180
Informação Relacionada: info:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F81604%2F2011/PT
Tipo de Documento: Artigo em Revista Científica Internacional
Condições de Acesso: openAccess
Licença: https://creativecommons.org/licenses/by/4.0/
Aparece nas coleções:I3S - Artigo em Revista Científica Internacional

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
10.1371-journal.pntd.0006180.pdf10.29 MBAdobe PDFThumbnail
Ver/Abrir


Este registo está protegido por Licença Creative Commons Creative Commons